先聲藥業(02096.HK)獲單抗Rademikibart大中華區獨家權利

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)獲單抗Rademikibart大中華區獨家權利

阿思達克 11-22 06:29

先聲藥業(02096.HK)公佈，與康乃德生物醫藥就創新藥單抗Rademikibart訂立獨家許可與合作協議。據此，集團將獲得在大中華地區開發、生產和商業化該產品所有適應症的獨家權利，公司將支付1.5億人民幣的首付款，達成指定開發和商業化里程碑後支付最多8.75億人民幣以及額外特許權使用費。

先声药业(02096.HK)

Relevant Stocks

先声药业(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)獲單抗Rademikibart大中華區獨家權利

Services

About Us

Agreement Statement